Search clinical trials for: XIENCE V®/ XIENCE PRIME™

Total 182 results

Abbott Medical Devices

Completed

XIENCE V: SPIRIT WOMEN

Myocardial Ischemia | Coronary Artery Disease | Coronary Arteriosclerosis | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Total Coronary Occlusion | Coronary Artery Restenosis

France, Italy, Norway, China, Spain, Germany, United Kingdom, Switzerland, Israel, Denmark, Belgium, Austria, Poland, Australia, Portugal, Argentina, Brazil, Hungary, Latvia, Netherlands, India, Greece, Malaysia, Russian Federation, South... and more
Abbott Medical Devices

Completed

XIENCE V: SPIRIT WOMEN Sub-study

Myocardial Ischemia | Coronary Artery Disease | Coronary Arteriosclerosis | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Total Coronary Occlusion | Coronary Artery Restenosis

Italy, Norway, Switzerland, Denmark, Spain, Poland, Belgium, Argentina, Austria, Brazil, France, Germany, Hungary, Latvia, Netherlands
Sino Medical Sciences Technology Inc.

Completed

A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT

Coronary Artery Disease | Stable Angina Pectoris | Unstable Angina Pectoris

China
Abbott Medical Devices

Completed

AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN)

Myocardial Ischemia | Coronary Artery Disease

Japan
Cardiovascular Research Foundation, New York
Dickson Advanced Analytics Group

Completed

Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES)

Coronary Artery Disease

United States
Abbott Medical Devices

Completed

Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France (Far XIENCE V®)

Coronary Artery Disease

France
Abbott Medical Devices

Completed

SPIRIT PRIME Clinical Trial (SPIRIT PRIME)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Restenosis | Coronary Artery Stenosis

United States, Australia
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Active, not recruiting

Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease | Antineoplastic Agents

China
Abbott Medical Devices

Completed

SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Netherlands, Thailand, Israel, Spain, Italy, United Kingdom, Malaysia, Austria, France, Germany, Poland
Deutsches Herzzentrum Muenchen

Unknown

Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents (ISAR-TEST6)

Coronary Heart Disease

Germany
Deutsches Herzzentrum Muenchen
Technical University of Munich

Completed

ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography (ORSIRO_OCT)

Coronary Heart Disease

Germany
Abbott Medical Devices

Completed

XIENCE PRIME Japan Post-Marketing Surveillance (PMS)

Myocardial Ischemia | Coronary Artery Disease | Coronary Occlusion | Coronary Artery Stenosis | Angina

Japan
Universitaire Ziekenhuizen KU Leuven
Biosensors International

Unknown

COmplex BifuRcation Lesions: a Comparison Between the AXXESS Device and Culotte Stenting: an Optical Coherence Tomography (OCT) Study (COBRA)

True Coronary Bifurcation Lesions

Belgium
European Cardiovascular Research Center

Unknown

Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization (PLATINUM+)

Ischemic Heart Disease | Coronary Artery Stenosis

Spain, Germany, France, United Kingdom, Italy, Netherlands, Macedonia, The Former Yugoslav Republic of, Switzerland
Amsterdam UMC, location VUmc

Unknown

Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study (VANISH)

Coronary Artery Disease

Netherlands
Cordis Corporation

Terminated

An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II) (NEVO II)

Atherosclerotic Coronary Artery Disease

Spain, Switzerland, Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA)

Myocardial Infarction | Coronary Artery Disease

Netherlands
Abbott Medical Devices

Completed

Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period (XERES)

Coronary Restenosis

France
Kobe University
Marquette University

Unknown

Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)

Coronary Heart Disease

Japan
Kobe University

Unknown

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent

Coronary Artery Disease

Japan
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) (XVU-LTF)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis

United States
Odense University Hospital

Completed

The SOURT OUT IV TRIAL (SORT OUT IV)

Ischemic Heart Disease | Percutaneous Coronary Intervention | Coronary Atherosclerosis

Denmark
Seoul National University Hospital

Completed

Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents (Grand-DES)

Coronary Artery Disease

Korea, Republic of
Policlinico Casilino ASL RMB
Azienda Ospedaliero-Universitaria di Modena

Withdrawn

Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus (OCELOT)

Coronary Artery Disease | Diabetes Mellitus

Italy
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus (ESSENCE-DM)

Coronary Artery Disease

Korea, Republic of
Odense University Hospital

Completed

Comparison of Coronary Xience V and the Cypher Select+ Stents in Diabetic Patients (DIABEDES IV)

Diabetes Mellitus

Denmark
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
Seung-Jung Park
Abbott; CardioVascular Research Foundation, Korea

Terminated

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Coronary Artery Disease

Korea, Republic of
Deutsches Herzzentrum Muenchen

Completed

Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography (TEST-6-OCT)

Coronary Heart Disease

Germany
Abbott Medical Devices

Completed

A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population (SV JAPAN)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Restenosis | Vascular Disease | Coronary Artery Stenosis

Japan
Flanders Medical Research Program

Completed

Drug Eluting Stents In The Critically Ischemic Lower Leg 2 (DESTINY 2)

Peripheral Arterial Disease

Germany, Australia, Belgium
Aarhus University Hospital Skejby
Medtronic; Abbott Medical Devices

Unknown

The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study (DOCTOR Recross)

Coronary Disease

United Kingdom, Belgium, Denmark
Seung-Jung Park
CardioVascular Research Foundation, Korea

Recruiting

Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice (IRIS Skypoint)

Coronary Artery Disease

Korea, Republic of
Abbott Medical Devices

Completed

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

Coronary Artery Disease

United States
Abbott Medical Devices

Completed

SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System (SPIRIT II)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Netherlands, Spain, Denmark, Germany, France, Austria, Belgium, India, Italy, New Zealand, Poland, South Africa, Switzerland
Abbott Medical Devices

Completed

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Myocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery Restenosis

United States
University of Jena
Boston Scientific Corporation; Abbott Medical Devices; B. Braun Melsungen AG

Completed

Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents (OCTOPUS)

Stents | Neointimal Proliferation

Germany
Abbott Medical Devices

Completed

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Stent Thrombosis | Coronary Restenosis | Chronic Coronary Occlusion | Vascular Disease | Coronary Artery Stenosis | Angina

Japan
North Texas Veterans Healthcare System

Completed

Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions (SOS-Xience V)

Coronary Artery Bypass | Atherosclerosis

United States
Biotronik AG

Unknown

Study of the Orsiro Drug Eluting Stent System (BIOFLOW-II)

Coronary Artery Disease

Latvia, Germany, Spain, Switzerland, Austria, France, Hungary, Netherlands
Sydney South West Area Health Service

Unknown

IVUS Controlled Stenting

Coronary Angioplasty and Stenting | Single de Novo Coronary Artery Stenoses

Australia
European Hospital

Completed

Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease (RENAL-DES)

Chronic Kidney Disease | Multivessel Coronary Artery Disease

Italy
Abbott Medical Devices

Completed

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA)

Coronary Artery Disease | Coronary Disease | Coronary Stenosis | Coronary Artery Stenosis

United States
The Hospital District of Satakunta

Completed

Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography (BASE-OCT)

Acute Coronary Syndrome

Finland
Lepu Medical Technology (Beijing) Co., Ltd.

Unknown

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Coronary Artery Disease

China
Shanghai MicroPort Medical (Group) Co., Ltd.

Completed

Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

Coronary Artery Disease

China
Shandong Branden Med.Device Co.,Ltd
Fudan University

Unknown

Cordimax China Post Market Surveillance

Coronary Artery Stenosis

China
Deutsches Herzzentrum Muenchen

Unknown

Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World (ZEPPELIN)

Coronary Artery Disease

Germany
Abbott Medical Devices

Completed

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Coronary Occlusion | Coronary Restenosis | Vascular Disease | Coronary Artery Stenosis | Thrombosis (Stent Thrombosis)

China

Search clinical trials for: XIENCE V®/ XIENCE PRIME™

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations